Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy

Munevver Sari1, Unal Erkorkmaz2, Hayrullah Yazar3

  • 1Department of Cardiology, University of Health Sciences, Kartal Kosuyolu Education and Research Hospital, Denizer street, 34865, Kartal/Istanbul, Turkey. benmsr@hotmail.com.

Herz
|December 11, 2019
PubMed

Insights

Patients with hypertrophic cardiomyopathy (HCM) exhibit altered serum thiol/disulphide homeostasis, indicating impaired antioxidant capacity. This suggests a potential link between HCM and oxidative stress similar to that observed in tumors.

Area of Science:

  • Biochemistry
  • Cardiology
  • Oxidative Stress Research

Background:

  • Hypertrophic cardiomyopathy (HCM) presents complex genetic factors and variable clinical outcomes.
  • Investigating non-genetic factors like oxidative stress is crucial for understanding HCM's heterogeneity.

Purpose of the Study:

  • To evaluate serum thiol/disulphide homeostasis as a marker of oxidative stress in patients with HCM.
  • To utilize a novel automated assay for precise measurement of thiol/disulphide balance.

Main Methods:

  • A cross-sectional study involving 119 HCM patients and 52 controls.
  • Measurement of dynamic thiol/disulphide homeostasis using calorimetric and duplex methods developed in 2014.

Main Results:

  • HCM patients showed significantly lower serum native thiol, total thiol, and disulphide levels compared to controls.
  • Disulphide/native thiol and disulphide/total thiol ratios were significantly lower in HCM patients.
  • Reduced thiol ratios were higher, and oxidized thiol ratios were lower in HCM patients, indicating impaired antioxidant capacity.

Conclusions:

  • HCM patients exhibit impaired antioxidant capacity, with serum thiol/disulphide homeostasis shifted towards a reducing state.
  • The study speculates that HCM may share similarities with tumors regarding serum thiol-disulphide level alterations.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
325
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
282
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
405
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
624
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
141
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
402